Expanding indications for liver transplantation in the era of liver transplant oncology

Table 2 Clinical trials in transplantation vs best medical therapy for liver-limited colorectal metastases

Ref.	Study	n	Characteristics	Intervention	Overall survival	Progression free survival
Hagness et al[75]	SECA-I	21	Unresectable; > 6 mo of neoadjuvant therapy	Liver transplant	5-yr OS: 60%	5-yr RFS: 33%
Dueland et al[68]	SECA-II	15	Unresectable; at least a 10% response to systemic therapy; disease stability 12 mo	Liver transplant	5-yr OS: 83%	3-yr RFS: 35%
Tveit et al[76]	NORDIC VII	566	Metastatic CRC; treatment-naïve; no resection with curative intent	A: FLOX alone; B: FLOX + Cetuximab; C: Cetuximab + Intermittent FLOX	3-yr OS: 6-8%	1-yr PFS: 20-32%

OS: Overall survival; PFS: Progression free survival; RFS: Recurrence free survival; CRC: Colorectal cancer.